Clinical Observation of Docetaxel Combined with Oxaliplatin Regimen for Advanced Gastric Cancer_West China Medical Journal

Authors：

 HANYi-chao ,  PENGYe , YANGXiu-fang , XIENa

Department of Oncology, Harrison International Peace Hospital, Hengshui, Hebei 053000, P. R. China;

Corresponding author：

PENGYe, Email: pengye666@sina.com

Keywords：

Docetaxel; Oxaliplatin; Chemotherapy; Advanced gastric cancer

DOI：

10.7507/1002-0179.20140620

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To evaluate the efficacy and safety of docetaxel (DOC) combined with oxaliplatin (OXA) regimen in the treatment of advanced gastric cancer. Methods Sixty patients with advanced gastric cancer treated in our hospital from January 2008 to January 2011 were randomly divided into two groups. The treatment group (n=30) was given DOC combined with OXA regimen. Patients in this group were treated with DOC 75 mg/m², ivgtt, d1; OXA 130 mg/m², ivgtt, d4; with 21 days as a cycle. The control group (n=30) was given DCF regimen. Patients in the control group were treated with DOC 75 mg/m², ivgtt, d1; cisplatin 75 mg/m², ivgtt, d1; calcium folinate 200/m², ivgtt, 2 h, d1-2; fluorouracil 400 mg/m², bolus 10 minutes, fluorouracil 600 mg/m² civ 22 h d1-2; also with 21 days as a cycle. All patients received two cycles of chemotherapy at least. The effective rate (complete remission+partial remission), adverse reactions, median survival time and quality of life were analyzed and compared between the two groups. Results The effective rates in the treatment group and the control group were 60.0% and 46.7% respectively, showing a non-significant difference (P>0.05). The appetite increasing rate (70.0% vs 43.3%), the weight gain rate (60.0% vs 33.3%), and the Karnofsky score improvement rate (63.3% vs 30.0%) of the treatment group were significantly higher than those of the control group (P<0.05). The adverse reactions were fewer in the treatment group, and most of them were between grade Ⅰ and Ⅱ. The median time of disease progression (5.8 months vs 5.6 months) and the median survival period (11.8 months vs 9.2 months) of the treatment group were longer than those in the control group. Conclusion DOC combined with OXA regimen is effective in treating advanced gastric cancer. It can significantly improve the quality of life of the patients, and it has fewer adverse reactions. Meanwhile, the median survival period is prolonged. DOC combined with OXA regimen is worth to be applied in clinic.

Citation： HANYi-chao, PENGYe, YANGXiu-fang, XIENa. Clinical Observation of Docetaxel Combined with Oxaliplatin Regimen for Advanced Gastric Cancer. West China Medical Journal, 2014, 29(11): 2055-2058. doi: 10.7507/1002-0179.20140620 Copy

1.	中国抗癌协会. 新编常见恶性肿瘤诊治规范[M]. 北京:中国协和医科大学出版社, 1999:105.
2.	Edge SB, Byrd DR, Compton CC, et al. AJCC cancer staging manual[M]. 7th ed. New York:Springer-Verlag, 2009:117-126.
3.	Ruiz-García V, Juan O, Pérez Hoyos S, et al. Megestrol acetate:a systematic review usefulness about the weight gain in neoplastic patients with cachexia[J]. Med Clin (Barc), 2002, 119(5):166-170.
4.	胡章华, 毛绍蓉. XELOX化疗方案用于老年晚期胃癌患者治疗的临床观察[J]. 重庆医学, 2013, 42(2):156-159.
5.	Ben Aharon I, Purim O, Kundel Y, et al. The combination of docetaxel, cisplatin, and 5-fluorouracil in advanced gastric cancer:a single-institution experience[J]. Anticancer Drugs, 2012, 23(3):313-320.
6.	张昉, 陈雅敏, 荆超, 等. 改良DCF方案与FOLFOX 4方案治疗晚期胃癌的临床疗效[J]. 临床肿瘤学杂志, 2014, 19(3):231-234.
7.	Chi Y, Ren JH, Yang L, et al. Phase Ⅱ clinical study on the modified DCF regimen for treatment of advanced gastric carcinoma[J]. Chin Med J (Engl), 2011, 124(19):2997-3002.
8.	吴芳, 张弘纲. 多西紫杉醇在晚期胃癌的临床应用[J]. 癌症进展, 2007, 5(3):276-281, 289.
9.	金懋林. 最新胃癌化学治疗方案[M]. 北京:北京科学技术出版社, 2003:15-16.
10.	吕慧芳, 张延新, 韩黎丽, 等. 奥沙利铂联合替吉奥或卡培他滨治疗老年晚期胃癌的临床观察[J]. 中国医药导报, 2012, 9(23):61-63.
11.	Kondoh C, Takahari D, Shitara K, et al. Efficacy of docetaxel in patients with paclitaxel-resistant advanced gastric cancer[J]. Gan To Kagaku Ryoho, 2012, 39(10):1511-1515.
12.	Choi YH, Oh SC, Kim JS, et al. A phase Ⅱ study of docetaxel and oxaliplatin combination in recurrent gastric cancer patients after fluoropyrimidine and/or cisplatin adjuvant treatment:a Korean Cancer Study Group Protocol ST06-02[J]. Cancer Chemother Pharmacol, 2012, 70(5):665-672.
13.	粱进, 毕清, 杨润祥. 多西他赛联合奥沙利铂治疗进展期胃癌的临床观察[J]. 实用癌症杂志, 2007, 22(5):501-502.
14.	陈绍俊, 黄海欣, 黄东宁, 等. 多西紫杉醇联合奥沙利铂每周疗法治疗30例高龄晚期胃癌的临床观察[J]. 四川医学, 2009, 30(11):1725-1727.
15.	叶珩, 钱科卿, 朱颖蔚. 多西紫杉醇联合氟尿嘧啶和奥沙利铂治疗晚期胃癌的临床观察[J]. 临床肿瘤学杂志, 2007, 12(10):763-764, 770.
16.	金建华, 李献文, 王芳, 等. 多西紫杉醇联合奥沙利铂、卡培他滨与FOLFOX4方案治疗晚期胃癌疗效比较[J]. 肿瘤防治研究, 2007, 34(11):873-876.

1. 中国抗癌协会. 新编常见恶性肿瘤诊治规范[M]. 北京:中国协和医科大学出版社, 1999:105.
2. Edge SB, Byrd DR, Compton CC, et al. AJCC cancer staging manual[M]. 7th ed. New York:Springer-Verlag, 2009:117-126.
3. Ruiz-García V, Juan O, Pérez Hoyos S, et al. Megestrol acetate:a systematic review usefulness about the weight gain in neoplastic patients with cachexia[J]. Med Clin (Barc), 2002, 119(5):166-170.
4. 胡章华, 毛绍蓉. XELOX化疗方案用于老年晚期胃癌患者治疗的临床观察[J]. 重庆医学, 2013, 42(2):156-159.
5. Ben Aharon I, Purim O, Kundel Y, et al. The combination of docetaxel, cisplatin, and 5-fluorouracil in advanced gastric cancer:a single-institution experience[J]. Anticancer Drugs, 2012, 23(3):313-320.
6. 张昉, 陈雅敏, 荆超, 等. 改良DCF方案与FOLFOX 4方案治疗晚期胃癌的临床疗效[J]. 临床肿瘤学杂志, 2014, 19(3):231-234.
7. Chi Y, Ren JH, Yang L, et al. Phase Ⅱ clinical study on the modified DCF regimen for treatment of advanced gastric carcinoma[J]. Chin Med J (Engl), 2011, 124(19):2997-3002.
8. 吴芳, 张弘纲. 多西紫杉醇在晚期胃癌的临床应用[J]. 癌症进展, 2007, 5(3):276-281, 289.
9. 金懋林. 最新胃癌化学治疗方案[M]. 北京:北京科学技术出版社, 2003:15-16.
10. 吕慧芳, 张延新, 韩黎丽, 等. 奥沙利铂联合替吉奥或卡培他滨治疗老年晚期胃癌的临床观察[J]. 中国医药导报, 2012, 9(23):61-63.
11. Kondoh C, Takahari D, Shitara K, et al. Efficacy of docetaxel in patients with paclitaxel-resistant advanced gastric cancer[J]. Gan To Kagaku Ryoho, 2012, 39(10):1511-1515.
12. Choi YH, Oh SC, Kim JS, et al. A phase Ⅱ study of docetaxel and oxaliplatin combination in recurrent gastric cancer patients after fluoropyrimidine and/or cisplatin adjuvant treatment:a Korean Cancer Study Group Protocol ST06-02[J]. Cancer Chemother Pharmacol, 2012, 70(5):665-672.
13. 粱进, 毕清, 杨润祥. 多西他赛联合奥沙利铂治疗进展期胃癌的临床观察[J]. 实用癌症杂志, 2007, 22(5):501-502.
14. 陈绍俊, 黄海欣, 黄东宁, 等. 多西紫杉醇联合奥沙利铂每周疗法治疗30例高龄晚期胃癌的临床观察[J]. 四川医学, 2009, 30(11):1725-1727.
15. 叶珩, 钱科卿, 朱颖蔚. 多西紫杉醇联合氟尿嘧啶和奥沙利铂治疗晚期胃癌的临床观察[J]. 临床肿瘤学杂志, 2007, 12(10):763-764, 770.
16. 金建华, 李献文, 王芳, 等. 多西紫杉醇联合奥沙利铂、卡培他滨与FOLFOX4方案治疗晚期胃癌疗效比较[J]. 肿瘤防治研究, 2007, 34(11):873-876.

Previous Article
Relationship between Clinicopathological Characteristics and Invasion Depth of Early Gastric Cancer
Next Article
Analysis of Clinical Laboratory Tests for Benign Prostatic Hyperplasia

West China Medical Journal

Clinical Observation of Docetaxel Combined with Oxaliplatin Regimen for Advanced Gastric Cancer

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content